Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-08-31 Governance Information
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
董事会秘书工作制度
Governance Information Classification · 95% confidence The document is titled "成都欧康医药股份有限公司董事会秘书工作制度" which translates to "Chengdu Oukang Pharmaceutical Co., Ltd. Board Secretary Work System." It details the internal management system for the company's board secretary, including qualifications, duties, appointment and dismissal procedures, and responsibilities. The document references the board meeting where this system was approved and includes detailed governance rules and procedures. There is no financial data, earnings information, or audit content. It is not a report of financial results or an announcement of voting results but a governance-related internal policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3131 characters, which is sufficient for a detailed governance report rather than a brief announcement.
2025-08-31 Chinese
董事会议事规则
Governance Information Classification · 95% confidence The document is titled "成都欧康医药股份有限公司董事会议事规则" which translates to "Chengdu Oukang Pharmaceutical Co., Ltd. Board Meeting Rules." It details the rules and procedures for the company's board of directors meetings, including composition, powers, meeting convocations, voting procedures, and record-keeping. There is no financial data, earnings information, or report content. It is a governance document outlining internal board rules and procedures. It is not an announcement of a report but the actual governance rules document. Therefore, it fits the category of Governance Information (CGR). The document length is sufficient and contains detailed governance content, confirming the classification with high confidence.
2025-08-31 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled "成都欧康医药股份有限公司关联交易管理制度" which translates to "Chengdu Oukang Pharmaceutical Co., Ltd. Related Party Transaction Management System." It is a detailed internal management system document regarding related party transactions, including definitions, principles, approval procedures, and voting rules. The document is issued by the company's board of directors and dated September 1, 2025. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for managing related party transactions, which falls under governance information. The document length is 7463 characters, indicating it is a full policy document rather than a brief announcement or notice. Therefore, the appropriate classification is Governance Information (CGR).
2025-08-31 Chinese
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 4th Board of Directors of Chengdu Oukang Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to other reports and announcements published elsewhere. The document does not contain the actual financial data or full reports but rather the board's decisions and approvals related to various reports and plans, such as the 2025 semi-annual report, fundraising usage report, and stock incentive plans. This type of document is a Board/Management Information announcement, as it focuses on board meeting resolutions and management decisions rather than the reports themselves or their publication announcements. The document length is 3209 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. Therefore, the correct classification is MANG (Board/Management Information).
2025-08-26 Chinese
监事会关于调整2024年股权激励计划限制性股票预留授予价格和数量的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of Chengdu Oukang Pharmaceutical Co., Ltd. regarding adjustments to the 2024 equity incentive plan, specifically the reserved grant price and quantity of restricted stocks. It references a previous announcement (2025-055) and confirms compliance with relevant stock exchange rules and company plans. The document is short (882 characters) and focuses on the supervisory board's verification and opinion on the adjustment, not the full equity incentive plan or detailed financial data. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about corporate governance and equity incentive adjustments, not a full management report, capital update, or remuneration report. Therefore, the classification is RNS with high confidence.
2025-08-26 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report". It covers the company's financial and operational performance for the period from January 1, 2025 to June 30, 2025, including detailed financial data such as revenue, profit, assets, liabilities, and cash flows. The document includes sections on accounting data, business overview, risk factors, and industry analysis. It explicitly states it is a half-year report and contains substantive financial statements and analysis, not just an announcement or summary. The length is substantial (15,000 characters), and it is not a certification or a brief announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.